Work

229: Twice-Daily Intravenous (IV) Busulfan (Bu) x 4 Days in Children Undergoing a Reduced-Intensity Conditioning (RIC) Regimen with Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT) is Safe and Well-Tolerated but Results in Significantly Increased Bu Clearance (CL) and Decreased Area Under the Curve (AUC) and Half-Life (t1/2) When Compared to IV Bu Twice-Daily Dosing Pharmacokinetics (PK) in Adults

Year: 2008

Type: article

Abstract: Inaccurate Bu dosing during HSCT conditioning can result in increased graft failure or excessive regimen-related toxicity. IV Bu is safe and effective in pediatric HSCT recipients at a dose of 4 mg/kg/day (≤4 yr) or 3.2 mg/kg/day (>4 yr) using q6 h × 16 dosing but Bu PK is age-dependent (Wall, Blood, 2000a). Q12 h × 8 dosing has been shown to be safe and effective in adults, with mean first-dose AUC 3576 mmol∗min, t1/2 3.46 h and CL 1.88 ml/min/kg (Fernandez, BBMT, 2002). However, Bu safety and PK data is lacking for q12 h × 8 dosing in pediatric HSCT recipients.

Source: Transplantation and Cellular Therapy

DOI: 10.1016/j.bbmt.2007.12.238